Airway Therapeutics

Based in Cincinnati, Ohio, Airway Therapeutics is a clinical-stage biopharmaceutical company developing novel biologic treatments for severe respiratory and inflammatory diseases. The pre-revenue biotechnology firm primarily focuses on its lead product candidate, AT-100, an engineered protein designed to reduce lung inflammation and infection in a target market of 160,000 preterm neonates annually across the United States and Europe. Operating with an estimated headcount of under 50 employees, the enterprise has secured significant capital, including a $54 million Series C financing round in 2021 backed by early institutional investors like CincyTech. The organization has received both Orphan Drug and Rare Pediatric Disease designations from the FDA while maintaining a strategic research partnership with Cincinnati Children's Hospital Medical Center. Airway Therapeutics was originally founded as a spin-out in 2011 by scientific researcher Dr. Jeffrey Whitsett.